Completed enrollment of Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled clinical trial of PCN-101 (R-ketamine). Last patient expected to be dosed this week, with the total number of patients expected to be around 100. Topline results expected around year-end 2022. PCN-101 is being investigated as a potentially rapid-acting therapeutic for treatment-resistant depression…


Previous articlePT367 – Colorado Proposition 122 and the Decriminalization of Natural Medicines
Next articleFree Webinar — Psychedelic Autism: A Brief Intro and Q&A with Aaron Orsini